Cogitum is an adaptogen with tonic and stimulating properties. It has a 40-year-long track record of successful application.

Cogitum is widely used in pediatrics and child neurology for treating delayed development, asthenic syndrome and for increasing endurance and mental performance in children and adolescents during high loads. The drug is prescribed in children aged 7 years and older. It enhances memory due to D-Aspartic acid which is a well-known metabolite.

Cogitum is well tolerated in children and has a significant effect. However it does not provide for an immediate effect as the child’s mental state improves gradually.

Cogitum is also a good option for adults in case of asthenia, heavy workload, recovery from different diseases or the need for increasing mental performance.

Pharmacodynamic properties

The drug is based on N-Acetylaspartic acid, which is a biologically active compound contained in the central nervous system (CNS). The drug stabilizes the nervous regulation and has a stimulating effect.

Indications:

  • as part of complex therapy of asthenic syndrome;
  • fatigue with/without low mood;
  • as an adjuvant for antidepressants;
  • in pediatrics Cogitum can be used as part of complex therapy of: intellectual disability, birth defects of the central nervous system, delayed mental and speech development, delay in motor skills development, etc.

Contradictions:

    • Hypersensitivity to N-Acetylaspartic acid or any other component of the drug
      Children under 7 years of age (no clinical data)
      Pregnancy (lack of clinical data)